placebo + standard of care

Placebo + standard of care (SOC) refers to the control intervention used in clinical trials sponsored by 101 Therapeutics for the treatment of COVID-19. In this regimen, patients receive an inactive placebo alongside the established medical protocols for hospitalized patients with moderate to severe disease. The standard of care component typically includes supportive measures such as supplemental oxygen or mechanical ventilation, as well as pharmacological agents like corticosteroids (e.g., dexamethasone) and antivirals (e.g., remdesivir), as dictated by local clinical guidelines and evolving treatment standards. This arm serves as a baseline to evaluate the incremental safety and therapeutic benefit of adding the investigational prodrug 101-PGC-005 to the existing treatment paradigm.

Other names

Placebo + SOCplacebo + standard of care-101 Therapeutics-COVID-19